Investigating the Effectiveness of Personalized Optimal Gamma Auditory Frequency Stimulation Intervention on Cognitive Function Enhancement

NCT07690865 | Not Yet Recruiting

• 1 other identifier: 202600632A3
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to evaluate whether personalized gamma-frequency auditory stimulation enhances cognitive function and brain synchronization. While 40 Hz auditory stimulation has been widely studied, recent evidence suggests optimal frequencies vary by individual. Using a cross-over design with 20 healthy adults, the research compares "optimal" versus "non-optimal" frequencies over one-month intervention periods. Effectiveness is measured through EEG recordings and executive function tasks. The goal is to determine if personalized sensory intervention provides a more effective, non-invasive strategy for enhancing cognitive performance.

Conditions

Gamma Oscillations; Healthy Adults; Alzheimer's Disease (AD); Gamma Entrainment Using Sensory Stimuli (GENUS)

Keywords

Gamma stimulation; Alzheimer's disease; EEG; cognitive function; intervention

Outcome Measures

Primary Outcomes (3)

• changes in neurophysiological function

  EEG oscillation within the gamma band obtained during resting-state and the periods of optimal and non-optimal auditory stimulation will be analyzed to evaluate and compare the neurophysiological changes.

  Stage 1 baseline (T1), post one-month intervention of stage 1 (T2), stage 2 baseline (T3), post one-month intervention of stage 2 (T4)

• changes in working memory performance

  Behavioral performance and electrophysiological activity will be evaluated via a working memory task.

  Stage 1 baseline (T1), post one-month intervention of stage 1 (T2), stage 2 baseline (T3), post one-month intervention of stage 2 (T4)

• changes in inhibitory control performance

  Behavioral performance and electrophysiological activity will be evaluated via an inhibitory control task.

  Stage 1 baseline (T1), post one-month intervention of stage 1 (T2), stage 2 baseline (T3), post one-month intervention of stage 2 (T4)

Study Arms (2)

Personalized optimal gamma auditory frequency stimulation

EXPERIMENTAL

The patient receives personalized optimal gamma auditory frequency stimulation at home for 1 month, 5 days per week, and 1 hour per day. The stimulation frequency is selected based on the frequency that produces the strongest neural entrainment.

Device: Personalized optimal gamma auditory frequency stimulation

Non-optimal gamma auditory frequency stimulation

ACTIVE COMPARATOR

The patient receives non-optimal gamma auditory frequency stimulation at home for 1 month, 5 days per week, and 1 hour per day. The stimulation frequency is selected based on the frequency that produces the weakest neural entrainment.

Device: Non-optimal gamma auditory frequency stimulation

Interventions

Personalized optimal gamma auditory frequency stimulation DEVICE

Participants will receive personalized optimal gamma auditory frequency stimulation using our app downloaded in the mobile device to play the sound for 1 hour per day, 5 days a week, over 1 month.

Personalized optimal gamma auditory frequency stimulation

Non-optimal gamma auditory frequency stimulation DEVICE

Participants will receive non-optimal gamma auditory frequency stimulation using our app downloaded in the mobile device to play the sound for 1 hour per day, 5 days a week, over 1 month.

Non-optimal gamma auditory frequency stimulation

Eligibility Criteria

• Age: 18 Years - 40 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Age between 18 to 40 years old.
• The Cognitive Abilities Screening Instrument (CASI) score is within normal ranges adjusted for age and education.
• Participants have no history of severe neurological or psychiatric disorders (such as stroke, epilepsy, depression, migraine, etc.) that could affect cognitive function.
• Participants have not used drugs that may affect cognitive function (e.g., benzodiazepines, anticholinergic medications, etc.).
• Participants with normal or corrected vision (e.g., glasses or contact lenses) to normal levels.
• Auditory stimuli induce significant neural entrainment.
• Self-reported normal hearing

You may not qualify if:

• Participants enrolled in any cognitive enhancement study within the past two months.
• Participants with a history of disease that could affect cognitive function (e.g., cancer, autoimmune diseases, etc.).
• Individuals with tinnitus or hyperacusis

Sponsors & Collaborators

• Chang Gung Memorial Hospital: lead

Study Sites (1)

Chang Gung University

Taoyuan, Guishan, 33302, Taiwan

Location

MeSH Terms

Conditions

Alzheimer Disease

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders

Central Study Contacts

Chia-Hsiung Cheng, Ph.D.

CONTACT

+886-3-211800; ch.cheng@mail.cgu.edu.tw

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 2, 2026
• First Posted: July 8, 2026
• Study Start: August 1, 2026
• Primary Completion (Estimated): September 1, 2027
• Study Completion (Estimated): December 1, 2027
• Last Updated: July 16, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

TW (1)